Advertisement Sosei acquires biotechnology company Heptares Therapeutics for $400m - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sosei acquires biotechnology company Heptares Therapeutics for $400m

Japanese biopharmaceutical company Sosei Group has acquired Heptares Therapeutics, in a deal worth $400m.

The acquisition forms a part of the company’s strategy to become a significant global biopharmaceutical company with drug discovery and clinical development capabilities for generating medicines.

With this acquisition, Sosei will secure Heptares’ StaR platform that has been used to generate a pipeline of new medicines with potential to transform the treatment of a wide range of human diseases.

Based in the UK, Heptares Therapeutics is a clinical-stage biotechnology company that develops medicines targeting G protein-coupled receptors (GPCRs).

It develops medicines targeting serious diseases with major unmet need such as Alzheimer’s disease, ADHD, metabolic disease, schizophrenia, migraine, among others.

Heptares will now become a wholly owned subsidiary of the Sosei, while continuing its existing R&D operations in the UK.

Sosei Group Corporation chairman and CEO Shinichi Tamura said: "Heptares is based on truly world-class science and its drug discovery and development capabilities will contribute to a sustainable stream of new products for the Group.

"While core to our future, an independent subsidiary structure will ensure Heptares is able to maintain the culture and business model that has been the foundation of its success so far."

The combined company will have access to global pharmaceutical markets; regulatory expertise across the EU, the US and Japan.